2026 Critical Care Congress Skip to main content
2026 Critical Care Congress Main banner
Final Program


Advance Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Thought Leader Session
Thought Leader Session
Guidelines Session
Guidelines Session
Aging Adult Track
Aging Adult Track
Additional Registration Fee
Additional Registration Fee

Sepsis
Concurrent

The Future of Sepsis and ARDS Therapy: Breakthroughs to Watch in 2026

Sunday, March 22, 2026
11:45 AM - 12:45 PM Central Time
Location: Skyline Ballroom, W375D

As we continue to move into 2026, the treatment landscape for sepsis and acute respiratory distress syndrome (ARDS) is undergoing a transformation. While standard supportive care remains critical, novel therapies targeting the underlying pathophysiology of these diseases have the potential to change ICU outcomes dramatically. From DPP3 modulation to TK inhibitors and interleukin-targeted therapies, the next generation of treatments offers promising strategies to mitigate organ dysfunction and improve survival. Speakers, who are leading experts in sepsis and ARDS research, will discuss cutting-edge developments, the science behind emerging therapies, and their clinical implications. Preclinical and clinical trial data, the mechanistic rationale for these interventions, and barriers to widespread adoption in critical care settings will be covered.

Learning Objectives:

  • Review the latest advancements in sepsis and ARDS therapies, including DPP3 inhibitors, tyrosine kinase (TK) inhibitors, and interleukin modulation.
  • Discuss the potential for these novel therapies to change the landscape of ICU treatment and improve patient outcomes.
  • Explore challenges in translating these scientific breakthroughs into clinical practice, including regulatory hurdles, trial design, and patient selection.

Presentations:

  • 11:50 AM - 12:05 PM Central Time
    Tyrosine Kinase Inhibitors: A Novel Approach to ARDS Therapy

    Derek Russell, Non-Member Physician

  • 12:05 PM - 12:20 PM Central Time
    Interleukin and Cytokine Modulation: Shaping the Immune Response in Sepsis and ARDS Using Precision Approaches

    Lorraine Ware, MD (she/her/hers) – Vanderbilt University

  • 12:20 PM - 12:30 PM Central Time
    Targeting DPP3: A New Frontier in Sepsis Management

    Kenneth Remy, MD, MSc, MSCI, FCCM – Case Western Reserve University/University Hospitals Cleveland Medical Center